Fulgent Genetics delivered the kind of quarter that changes the near-term narrative without fully resolving the long-term one. The company reported a loss of $0.38 per share on revenue of $90.41 million, against a consensus loss of $1.00 and revenue expectations of $86.3 million. That was a 62.0% earnings surprise and a 4.8% revenue beat. Earnings fell 137.5% from a year ago, while revenue grew 7.5%. The figures depend on the basis used. The company reported a GAAP loss of $0.48 and a non-GAAP loss of $0.09, compared with non-GAAP earnings of $0.14 a year earlier. On any measure, Fulgent remains loss-making where it was profitable on an adjusted basis last year. The central takeaway is that Q3 marked a clear sequential turn after the Q2 guide-down, driven primarily by fixing a self-inflicted billing problem rather than by a demand inflection.

The quality of the beat deserves scrutiny. Non-GAAP gross margin recovered to 36.3% from 31.3% in Q2 and 32.3% in Q1. CFO Paul Kim credited improved collection rates as the company worked through its billing system issue. Non-GAAP operating margin improved to -13.2% from -26.2% the prior quarter. Adjusted EBITDA loss narrowed to $7.5 million from $17.1 million. Measured year over year, however, the picture is far less flattering. Gross margin is still roughly eight points below the 44.3% posted a year ago, and the non-GAAP operating margin compares with -4.2% in the prior-year quarter. Q3 operating expenses also benefited from a $3.2 million bad-debt recovery, which inflates the sequential margin improvement. The headline beat is real, but part of it reflects reversal of earlier damage.

The revenue mix reveals a more uncomfortable trend. Sequential growth was solid: revenue rose 6% from $85.4 million in Q2 and from $71.1 million in Q1. Anatomic pathology jumped 57% year over year to $40.9 million, but the Bako and StrataDx acquisitions contributed $21.8 million of that. Acquired revenue therefore exceeded the entire year-over-year top-line gain, which implies the legacy base contracted. Precision diagnostics fell 18% as the largest customer continued in-sourcing, and management trimmed the top end of that segment's full-year guide to $161-165 million. Biopharma services was a bright spot at $7.7 million, up 19% sequentially, with its full-year range nudged up to $23-25 million. Demand, in aggregate, looks flat.

Guidance captures the same split. Management reaffirmed 2026 revenue of $330-340 million, still well below the original $350 million target, and the midpoint implies Q4 roughly flat with Q3. Everything below the revenue line moved up:

• The non-GAAP loss outlook improved to $1.65-$1.75 per share from $2.22-$2.35 on the Q2 call.
• The operating margin outlook moved to the low negative-20s.
• Year-end cash guidance rose to $630 million from $610 million, aided by a $112.3 million federal tax refund.
• Therapeutic development spend was cut to roughly $21 million from $26 million.

The per-share improvement also benefits from 4.1 million fewer shares following $64.1 million of year-to-date buybacks, although the cash guide assumes no further near-term repurchases.

The forward catalysts are real but carry asterisks. FID-007 completed its end-of-Phase II FDA meeting in August and Phase III preparation is underway. The prior first-half 2027 start was not explicitly reiterated, however, and partnering remains unresolved. The AI pathology platform is scaling, with about 255,000 slides analyzed, up 23% sequentially, four modules in production and five more planned for Q4. Management said the billing fine-tuning is incomplete and gave no timeline for a return to historical collection rates. FY2027 guidance on the next call will be the true test.

The market setup is more complicated than the surprise implies. Shares had climbed 13.6% since the open following the July report to $19.68 heading into this release. That leaves them just 2.1% above the 200-day moving average and 13.6% below the October 6 inter-earnings high of $22.78, after a rally from the $16.05 low set the day after the last report. Investor sentiment remained negative and weakened modestly, slipping from -0.34 to -0.39, so expectations were not elevated going in. Price, sequential-growth and AVWAP trend readings are positive, while momentum remains negative.

The bottom line is that Fulgent proved the billing-driven margin collapse is reversing faster than management expected, and the improved loss and cash outlook is backed by a $652.4 million balance sheet. Bears still have legitimate ammunition: organic revenue is shrinking beneath acquired growth, the largest customer keeps pulling volume, and guidance embeds no Q4 acceleration. Q3 repaired the damage; it did not yet demonstrate durable growth.